JP2023549322A - 治療学的酵素融合タンパク質のファブリー病に起因する又は伴うニューロパチーの予防及び治療用途 - Google Patents
治療学的酵素融合タンパク質のファブリー病に起因する又は伴うニューロパチーの予防及び治療用途 Download PDFInfo
- Publication number
- JP2023549322A JP2023549322A JP2023525997A JP2023525997A JP2023549322A JP 2023549322 A JP2023549322 A JP 2023549322A JP 2023525997 A JP2023525997 A JP 2023525997A JP 2023525997 A JP2023525997 A JP 2023525997A JP 2023549322 A JP2023549322 A JP 2023549322A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- enzyme
- region
- amino acid
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152246 | 2020-11-13 | ||
| KR10-2020-0152246 | 2020-11-13 | ||
| PCT/KR2021/016629 WO2022103220A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549322A true JP2023549322A (ja) | 2023-11-24 |
| JP2023549322A5 JP2023549322A5 (https=) | 2024-11-25 |
Family
ID=81601490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525997A Pending JP2023549322A (ja) | 2020-11-13 | 2021-11-15 | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴うニューロパチーの予防及び治療用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230416714A1 (https=) |
| EP (1) | EP4245310A4 (https=) |
| JP (1) | JP2023549322A (https=) |
| KR (1) | KR20220065720A (https=) |
| CN (1) | CN116419759A (https=) |
| AU (1) | AU2021377712A1 (https=) |
| CA (1) | CA3196264A1 (https=) |
| CO (1) | CO2023006516A2 (https=) |
| IL (1) | IL302857A (https=) |
| MX (1) | MX2023005579A (https=) |
| WO (1) | WO2022103220A1 (https=) |
| ZA (1) | ZA202304536B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230134823A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019125059A1 (ko) * | 2017-12-22 | 2019-06-27 | 한미약품 주식회사 | 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| WO2018127920A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| AU2018295994B2 (en) * | 2017-07-07 | 2025-02-06 | Hanmi Pharm. Co., Ltd. | Novel therapeutic enzyme fusion protein and use thereof |
-
2021
- 2021-11-15 US US18/036,538 patent/US20230416714A1/en active Pending
- 2021-11-15 MX MX2023005579A patent/MX2023005579A/es unknown
- 2021-11-15 JP JP2023525997A patent/JP2023549322A/ja active Pending
- 2021-11-15 AU AU2021377712A patent/AU2021377712A1/en active Pending
- 2021-11-15 IL IL302857A patent/IL302857A/en unknown
- 2021-11-15 WO PCT/KR2021/016629 patent/WO2022103220A1/ko not_active Ceased
- 2021-11-15 KR KR1020210156862A patent/KR20220065720A/ko active Pending
- 2021-11-15 CN CN202180075085.8A patent/CN116419759A/zh active Pending
- 2021-11-15 EP EP21892387.8A patent/EP4245310A4/en active Pending
- 2021-11-15 CA CA3196264A patent/CA3196264A1/en active Pending
-
2023
- 2023-04-19 ZA ZA2023/04536A patent/ZA202304536B/en unknown
- 2023-05-17 CO CONC2023/0006516A patent/CO2023006516A2/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019125059A1 (ko) * | 2017-12-22 | 2019-06-27 | 한미약품 주식회사 | 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도 |
Non-Patent Citations (1)
| Title |
|---|
| 衛藤 義勝 ほか: "ファブリー病患者に対するα-ガラクトシダーゼA補充療法の多施設臨床試験成績", 小児科臨床, vol. 第56巻,第1号, JPN6025044677, 2003, pages 133 - 143, ISSN: 0005811693 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230416714A1 (en) | 2023-12-28 |
| AU2021377712A9 (en) | 2024-07-11 |
| ZA202304536B (en) | 2024-09-25 |
| EP4245310A4 (en) | 2024-10-30 |
| AU2021377712A1 (en) | 2023-06-01 |
| CA3196264A1 (en) | 2022-05-19 |
| IL302857A (en) | 2023-07-01 |
| KR20220065720A (ko) | 2022-05-20 |
| MX2023005579A (es) | 2023-05-29 |
| WO2022103220A1 (ko) | 2022-05-19 |
| CN116419759A (zh) | 2023-07-11 |
| CO2023006516A2 (es) | 2023-06-09 |
| EP4245310A1 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9458214B2 (en) | Dual function fibroblast growth factor 21 proteins | |
| US12435328B2 (en) | Therapeutic enzyme fusion protein having a novel structure and use thereof | |
| CN107995914A (zh) | 人成纤维细胞生长因子21融合蛋白及其制备方法与用途 | |
| JP7697784B2 (ja) | 新規治療学的酵素融合タンパク質及びその用途 | |
| CN110028587A (zh) | 用于调节血糖和脂质的增效型双功能蛋白 | |
| JP2023549322A (ja) | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴うニューロパチーの予防及び治療用途 | |
| KR20220022899A (ko) | 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법 | |
| JP2023549323A (ja) | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 | |
| JP2020528756A (ja) | イズロン酸−２−スルファターゼ結合体 | |
| US20230372448A1 (en) | Therapeutic use of long-acting conjugate of triple agonist acting on all of glucagon, glp-1 and gip receptors against multiple sclerosis | |
| HK40096918A (en) | Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's disease | |
| US20230355789A1 (en) | Therapeutic use, for neurodegenerative diseases, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof | |
| HK40096917A (en) | Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease | |
| CA3085252A1 (en) | Dual-function protein for lipid and blood glucose regulation | |
| EA051314B1 (ru) | Применение слитого с терапевтическим ферментом белка для предупреждения и лечения нейропатии, считающейся следствием болезни фабри или ассоциированной с болезнью фабри | |
| US20230390362A1 (en) | Use of trigonal agonist having activities to all of glucagon, glp-1, and gip receptors in treatment of sequelae following respiratory infectious diseases | |
| EA051281B1 (ru) | Применение слитого с терапевтическим ферментом белка для предупреждения и лечения почечного заболевания, вызванного или связанного с болезнью фабри | |
| KR20230095666A (ko) | 간 표적 물질 및 이의 용도 | |
| HK40018046A (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| AU2020204470B1 (en) | Dual-function protein for lipid and blood glucose regulation | |
| HK40067345B (en) | Method for preparing long-acting drug conjugate through preparation of novel intermediate | |
| HK1106445A1 (en) | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260309 |